Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

, KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

09:39
11/23/16
11/23
09:39
11/23/16
09:39

TheStreet's Feuerstein says 'highly likely' FDA shuts down Juno

TheStreet's Adam Feuerstein said via Twitter, "Seems highly likely, necessary, for FDA to shut down $JUNO entirely, all CAR-T programs, until they figure out what is going wrong." Along with Juno Therapeutics (JUNO), other companies developing CAR-T programs include Kite Pharma (KITE), ZIOPHARM (ZIOP) and bluebird bio (BLUE).

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

ZIOP

Ziopharm

$6.14

-0.27 (-4.21%)

BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

  • 23

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 03

    Dec

JUNO Juno Therapeutics
$29.88

-1.56 (-4.96%)

11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Juno Therapeutics drug could deliver best in class data, says SunTrust
SunTrust analyst Peter Lawson says that Juno's non-Hodgkin lymphoma,treatment, JCAR017, could deliver best in class data at ASH. The analyst reiterates a $48 price target and a Buy rating on the shares.
11/04/16
BTIG
11/04/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
BTIG analyst Dane Leone upgraded Juno Therapeutics (JUNO) to Neutral from Sell citing valuation following the ASH abstract release showed similar response rates for JCAR017 versus Kite's (KITE) KTE-C19 in the treatment of patients with Diffuse Large B-Cell Lymphoma.
11/03/16
BTIG
11/03/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
11/23/16
JANY
11/23/16
NO CHANGE
JANY
Weakness in bluebird bio unwarranted after Juno trial halt, says Janney Capital
KITE Kite Pharma
$51.69

-1.99 (-3.71%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
ZIOP Ziopharm
$6.14

-0.27 (-4.21%)

12/04/15
12/04/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Affimed Therapeutics (AFMD) initiated with an Outperform at Wells Fargo... American Farmland (AFCO) initiated with an Outperform at Raymond James... Amgen (AMGN) initiated with a Market Perform at Wells Fargo... Applied Genetic (AGTC) initiated with an Outperform at Wells Fargo... BCE (BCE) initiated with a Buy at Goldman... Capital Product (CPLP) initiated with a Buy at Janney Capital... Celestica (CLS) initiated with a Neutral at B. Riley... Colfax (CFX) initiated with a Perform at Oppenheimer... Dimension Therapeutics (DMTX) initiated with an Outperform at Wells Fargo... Dover (DOV) initiated with a Perform at Oppenheimer... Fate Therapeutics (FATE) initiated with an Outperform at Wells Fargo... FibroGen (FGEN) initiated with a Buy at Citi... Finish Line (FINL) initiated with a Hold at BB&T... Five Prime (FPRX) resumed with an Outperform at Wells Fargo... Foot Locker (FL) initiated with a Buy at BB&T... GWG Holdings (GWGH) initiated with a Buy at Roth Capital... General Growth (GGP) initiated with an Outperform at Boenning & Scattergood... GigOptix (GIG) initiated with a Buy at Sterne Agee CRT... Halozyme (HALO) initiated with an Outperform at Wells Fargo... Hasbro (HAS) initiated with a Hold at Jefferies... Infinera (INFN) initiated with an Outperform at Raymond James... Inphi (IPHI) initiated with a Buy at Sterne Agee CRT... Inter Parfums (IPAR) initiated with an Overweight at KeyBanc... Intercept (ICPT) initiated with a Market Perform at Wells Fargo... Isis Pharmaceuticals (ISIS) initiated with an Outperform at Wells Fargo... LinkedIn (LNKD) initiated with a Buy at Nomura... Macerich (MAC) initiated with an Outperform at Boenning & Scattergood... Markit (MRKT) initiated with a Hold at Cantor... Mattel (MAT) initiated with a Buy at Jefferies... Maximus (MMS) initiated with a Buy at Stifel... MyoKardia (MYOK) initiated with an Outperform at Wells Fargo... Nimble Storage (NMBL) initiated with an Overweight at JPMorgan... OncoMed (OMED) initiated with an Outperform at Wells Fargo... Patriot National (PN) initiated with a Buy at Compass Point... Pennsylvania REIT (PEI) initiated with a Neutral at Boenning & Scattergood... Pixelworks (PXLW) initiated with a Buy at Craig-Hallum... Qualcomm (QCOM) initiated with an Overweight at Pacific Crest... Regeneron (REGN) initiated with an Outperform at Wells Fargo... Regulus (RGLS) initiated with an Outperform at Wells Fargo... Rogers Communications (RCI) initiated with a Neutral at Goldman... Rouse Properties (RSE) initiated with a Neutral at Boenning & Scattergood... Sangamo (SGMO) initiated with an Outperform at Wells Fargo... Sanmina (SANM) initiated with a Buy at B. Riley... Simon Property (SPG) initiated with an Outperform at Boenning & Scattergood... TELUS (TU) initiated with a Neutral at Goldman... TESARO (TSRO) initiated with an Outperform at Wells Fargo... Tokai Pharmaceuticals (TKAI) initiated with an Outperform at Wells Fargo... Vitae Pharmaceuticals (VTAE) initiated with an Outperform at Wells Fargo... ZIOPHARM (ZIOP) initiated with an Underperform at Wells Fargo... bluebird bio (BLUE) initiated with an Outperform at Wells Fargo.
06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
ZIOPHARM initiated with a Market Perform at Raymond James
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
08/10/16
WELS
08/10/16
UPGRADE
WELS
Market Perform
ZIOPHARM upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded ZIOPHARM Oncology to Market Perform citing valuation following the company's Q2 results. The analyst keeps a $5-$8 price target range for the shares.
BLUE bluebird bio
$60.95

-1.55 (-2.48%)

11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
BMO Capital initiated bluebird bio with a Market Perform rating and $61 price target.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
Analyst Matthew Luchini initiated bluebird with a Market Perform and a $61 price target.
11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ITRI

Itron

$76.50

3.7 (5.08%)

, SSNI

Silver Spring

$16.10

3.1 (23.85%)

07:30
09/19/17
09/19
07:30
09/19/17
07:30
Downgrade
Itron, Silver Spring rating change  »

Itron downgraded to Hold…

ITRI

Itron

$76.50

3.7 (5.08%)

SSNI

Silver Spring

$16.10

3.1 (23.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOBE

Bob Evans

$72.93

1.02 (1.42%)

07:30
09/19/17
09/19
07:30
09/19/17
07:30
Hot Stocks
Breaking Hot Stocks news story on Bob Evans »

Bob Evans trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.42

0.32 (0.86%)

, CRM

Salesforce

$95.74

1.11 (1.17%)

07:30
09/19/17
09/19
07:30
09/19/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

T

AT&T

$37.42

0.32 (0.86%)

CRM

Salesforce

$95.74

1.11 (1.17%)

AXON

Axovant Sciences

$22.88

1.54 (7.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 29

    Nov

Q

QuintilesIMS

$95.07

0.6 (0.64%)

07:29
09/19/17
09/19
07:29
09/19/17
07:29
Initiation
QuintilesIMS initiated  »

QuintilesIMS initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$24.35

1.77 (7.84%)

07:27
09/19/17
09/19
07:27
09/19/17
07:27
Recommendations
Meritor analyst commentary  »

Meritor price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAA

Under Armour

$17.37

-0.42 (-2.36%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Technical Analysis
Technical View: Under Armour falls, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

CAH

Cardinal Health

$67.07

-0.43 (-0.64%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Initiation
Cardinal Health initiated  »

Cardinal Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

HAS

Hasbro

$93.24

-1.6 (-1.69%)

, MAT

Mattel

$14.87

-0.99 (-6.24%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Hot Stocks
Toys"R"Us confirms filing Chapter 11 bankruptcy petitions in U.S. »

Toys"R"Us…

HAS

Hasbro

$93.24

-1.6 (-1.69%)

MAT

Mattel

$14.87

-0.99 (-6.24%)

JAKK

JAKKS Pacific

$2.85

-0.2 (-6.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, FB

Facebook

$170.01

-1.63 (-0.95%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Recommendations
Amazon.com, Facebook, Alphabet, Alphabet Class A, Activision Blizzard, Electronic Arts, Take-Two analyst commentary  »

KeyBanc remains positive…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

FB

Facebook

$170.01

-1.63 (-0.95%)

GOOG

Alphabet

$915.00

-5.29 (-0.57%)

GOOGL

Alphabet Class A

$929.75

-5.54 (-0.59%)

ATVI

Activision Blizzard

$64.20

-0.8 (-1.23%)

EA

Electronic Arts

$119.96

0.54 (0.45%)

TTWO

Take-Two

$100.82

0.43 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

ACDVF

Air Canada

$19.26

-0.7713 (-3.85%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Air Canada to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

XLRN

Acceleron

$39.38

-0.53 (-1.33%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Acceleron to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

BIG

Big Lots

$49.05

-0.97 (-1.94%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Big Lots to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 27

    Sep

CALD

Callidus Software

$26.05

0.55 (2.16%)

07:25
09/19/17
09/19
07:25
09/19/17
07:25
Conference/Events
Callidus Software to host analyst day »

Analyst Day to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ONB

Old National Bancorp

$16.70

0.3 (1.83%)

07:24
09/19/17
09/19
07:24
09/19/17
07:24
Upgrade
Old National Bancorp rating change  »

Old National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABC

AmerisourceBergen

$80.67

-0.93 (-1.14%)

07:24
09/19/17
09/19
07:24
09/19/17
07:24
Initiation
AmerisourceBergen initiated  »

AmerisourceBergen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

MDGS

Medigus

$2.03

0.08 (4.10%)

07:22
09/19/17
09/19
07:22
09/19/17
07:22
Technical Analysis
Technical View: Medigus moves up sharply in early trading »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

07:21
09/19/17
09/19
07:21
09/19/17
07:21
Initiation
Walgreens Boots Alliance initiated  »

Walgreens Boots Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

CMG

Chipotle

$301.87

-11.22 (-3.58%)

07:21
09/19/17
09/19
07:21
09/19/17
07:21
Periodicals
Customers criticize Chipotle's 'queso' dip on social media, Reuters reports »

Shares of Chipotle are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$14.89

-0.18 (-1.19%)

07:20
09/19/17
09/19
07:20
09/19/17
07:20
Initiation
ZTO Express initiated  »

ZTO Express initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$16.75

0.64 (3.97%)

07:20
09/19/17
09/19
07:20
09/19/17
07:20
Hot Stocks
Synchronoss drops 12% after Siris withdraws acquisition interest »

Siris Capital Group on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$16.75

0.64 (3.97%)

07:19
09/19/17
09/19
07:19
09/19/17
07:19
Technical Analysis
Technical View: Synchronoss falls sharply after Siris drops all-cash offer »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$83.31

0.14 (0.17%)

07:18
09/19/17
09/19
07:18
09/19/17
07:18
Initiation
CVS Health initiated  »

CVS Health initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 17

    Oct

MZOR

Mazor Robotics

$46.99

2.29 (5.12%)

07:16
09/19/17
09/19
07:16
09/19/17
07:16
Hot Stocks
Migdal takes 4.92% passive stake in Mazor Robotics »

Migdal Insurance &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

THS

TreeHouse

$67.29

0.08 (0.12%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Initiation
TreeHouse initiated  »

TreeHouse reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBC

Wabco

, MTOR

Meritor

$24.35

1.77 (7.84%)

07:15
09/19/17
09/19
07:15
09/19/17
07:15
Recommendations
Wabco, Meritor analyst commentary  »

Wabco price target raised…

WBC

Wabco

MTOR

Meritor

$24.35

1.77 (7.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.